抗抑郁药转换与增效治疗对难治性重性抑郁障碍缓解的影响:VAST-D随机临床试验
该研究纳入美国35家退伍军人健康管理局医疗中心的1522例对至少一种抗抑郁药足量足疗程无效的非精神病性重性抑郁障碍患者,随机分为转换为安非他酮、安非他酮增效或阿立哌唑增效三组。12周时阿立哌唑增效组缓解率28.9%高于转换组22.3%(RR 1.30,95%CI 1.05-1.60;P=0.02),其他缓解比较无显著差异;阿立哌唑组应答率也较高,但更多出现嗜睡、静坐不能和体重增加。
要点
- 阿立哌唑增效组12周缓解率28.9%,高于安非他酮转换组的22.3%(RR 1.30,95%CI 1.05-1.60)。
- 阿立哌唑增效组应答率74.3%,高于转换组62.4%和安非他酮增效组65.6%。
- 阿立哌唑组嗜睡、静坐不能和体重增加更常见;安非他酮两组焦虑更频繁。
核心结论
- 在以男性为主的对治疗无反应的重性抑郁障碍患者中,与转换为安非他酮单药治疗相比,阿立哌唑增效在12周治疗期间带来统计学显著但幅度不大的缓解可能性增加。
- 鉴于效应量小及阿立哌唑相关不良反应,作者认为需要进一步分析包括成本效益,以理解该方法的净效用。
研究设计与样本
- 研究为随机临床试验,于2012年12月至2015年5月在美国35家退伍军人健康管理局医疗中心开展。
- 共纳入1522例非精神病性重性抑郁障碍患者,对至少1种符合最低剂量和疗程标准的抗抑郁药治疗无反应,按1:1:1随机分配,评估最长36周。
- 急性治疗期12周,延续期随访最长36周;随机分组为转换组511例、安非他酮增效组506例、阿立哌唑增效组505例。
主要发现
- 1522例随机患者平均年龄54.4岁,男性1296例(85.2%),1137例(74.7%)完成急性治疗期。
- 12周缓解率:转换组22.3%(n=114),安非他酮增效组26.9%(n=136),阿立哌唑增效组28.9%(n=146)。
- 阿立哌唑增效组缓解率高于转换组(RR 1.30,95%CI 1.05-1.60;P=0.02),其他缓解比较无显著差异。
- 应答率:阿立哌唑增效组74.3%,高于转换组62.4%(RR 1.19,95%CI 1.09-1.29)和安非他酮增效组65.6%(RR 1.13,95%CI 1.04-1.23)。
- 复发无显著治疗差异;焦虑在安非他酮两组更频繁:转换组24.3%(n=124)vs 阿立哌唑增效组16.6%(n=84),安非他酮增效组22.5%(n=114)。
关键数值与推荐
- 主要结局为急性治疗期缓解,定义为QIDS-C16评分≤5且连续2次访视达标。
- 次要结局包括应答(QIDS-C16评分降低≥50%或临床总体印象改善量表改善)、复发和不良反应。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出阿立哌唑效应量小且伴不良反应,需进一步分析包括成本效益以理解该方法的净效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. OBJECTIVE: To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. DESIGN, SETTING, AND PARTICIPANTS: From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study. Patients were randomly assigned (1:1:1) to 1 of 3 treatments and evaluated for up to 36 weeks. INTERVENTIONS: Switch to a different antidepressant, bupropion (switch group, n = 511); augment current treatment with bupropion (augment-bupropion group, n = 506); or augment with an atypical antipsychotic, aripiprazole (augment-aripiprazole group, n = 505) for 12 weeks (acute treatment phase) and up to 36 weeks for longer-term follow-up (continuation phase). MAIN OUTCOMES AND MEASURES: The primary outcome was remission during the acute treatment phase (16-item Quick Inventory of Depressive Symptomatology-Clinician Rated [QIDS-C16] score ≤5 at 2 consecutive visits). Secondary outcomes included response (≥50% reduction in QIDS-C16 score or improvement on the Clinical Global Impression Improvement scale), relapse, and adverse effects. RESULTS: Among 1522 randomized patients (mean age, 54.4 years; men, 1296 [85.2%]), 1137 (74.7%) completed the acute treatment phase. Remission rates at 12 weeks were 22.3% (n = 114) for the switch group, 26.9% (n = 136)for the augment-bupropion group, and 28.9% (n = 146) for the augment-aripiprazole group. The augment-aripiprazole group exceeded the switch group in remission (relative risk [RR], 1.30 [95% CI, 1.05-1.60]; P = .02), but other remission comparisons were not significant. Response was greater for the augment-aripiprazole group (74.3%) than for either the switch group (62.4%; RR, 1.19 [95% CI, 1.09-1.29]) or the augment-bupropion group (65.6%; RR, 1.13 [95% CI, 1.04-1.23]). No significant treatment differences were observed for relapse. Anxiety was more frequent in the 2 bupropion groups (24.3% in the switch group [n = 124] vs 16.6% in the augment-aripiprazole group [n = 84]; and 22.5% in augment-bupropion group [n = 114]). Adverse effects more frequent in the augment-aripiprazole group included somnolence, akathisia, and weight gain. CONCLUSIONS AND RELEVANCE: Among a predominantly male population with major depressive disorder unresponsive to antidepressant treatment, augmentation with aripiprazole resulted in a statistically significant but only modestly increased likelihood of remission during 12 weeks of treatment compared with switching to bupropion monotherapy. Given the small effect size and adverse effects associated with aripiprazole, further analysis including cost-effectiveness is needed to understand the net utility of this approach. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01421342.
引用
- Mohamed S, Johnson GR, Chen P, et al. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA. 2017. PMID: 28697253. doi:10.1001/jama.2017.8036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。